Sol-Gel Discontinues SGT-210 Development for Darier Disease After Phase 1b Trial Fails to Show Efficacy
Key Insights
Sol-Gel Technologies announced that its Phase 1b proof-of-concept study of SGT-210 for Darier disease (search) failed to demonstrate superiority over vehicle control in efficacy assessments.
The company has decided to discontinue development of SGT-210 for Darier disease (search) and will instead pursue small feasibility studies in other areas where the drug's mechanistic rationale is stronger.
Sol-Gel will continue prioritizing its Phase 3 program of SGT-610 for Gorlin syndrome (search) prevention and potential Phase 3 development in high-frequency basal cell carcinoma (search).
Sol-Gel Technologies announced the discontinuation of SGT-210 development for Darier disease (search) following disappointing results from its vehicle-controlled Phase 1b proof-of-concept study. The dermatology company revealed that unblinded clinical data showed no differentiation between SGT-210 and vehicle control on the study's efficacy assessments.
Strategic Pivot Following Trial Results
Executive Chairman Mori Arkin stated that after unblinding the clinical data, "the study did not demonstrate a signal of superiority of active treatment versus vehicle, and we have therefore decided not to advance to the next stage of development in this indication." The company plans to redirect resources toward small, low-cost feasibility studies in other areas of unmet medical need where SGT-210's mechanistic rationale shows stronger potential.
Focus Shifts to Gorlin Syndrome Program
Sol-Gel will continue prioritizing the successful completion of its Phase 3 program of SGT-610 in Gorlin syndrome (search) and preparatory activities supporting a potential Phase 3 program in high-frequency basal cell carcinoma (search) (BCC), subject to successful completion of the Gorlin Phase 3 trial.
SGT-610 Mechanism and Potential
SGT-610, a hedgehog signaling pathway (search) blocker, has the potential to become the first ever treatment for prevention of BCCs in Gorlin syndrome (search) patients, if approved. The drug contains patidegib as its active substance, designed to block the smoothened, frizzle class receptor (SMO (search)) signal, allowing cells to function normally and reducing new tumor production.
Understanding Gorlin Syndrome
Gorlin syndrome (search) affects approximately 1 in 27,000-31,000 people in the U.S. and represents an autosomal dominant genetic disorder mostly caused by inheritance of one defective copy of the tumor suppressor patched homolog 1 (PTCH1 (search)) gene. Under normal conditions, the PTCH1 gene blocks the SMO (search) gene, turning off the hedgehog signaling pathway (search) when not needed. However, mutations in the PTCH1 gene may cause loss of PTCH1 function, release of SMO, and allow BCC tumor cells to divide uncontrollably.
Company Portfolio and Pipeline
Sol-Gel Technologies maintains an established dermatology portfolio including FDA-approved TWYNEO for acne vulgaris (search) treatment in adults and pediatric patients nine years of age and older, and EPSOLAY for inflammatory lesions of rosacea (search) in adults. The company's pipeline features SGT-610 as an Orphan and breakthrough drug candidate in Phase 3 clinical trials, positioned as a new topical hedgehog inhibitor expected to have an improved safety profile compared to oral hedgehog inhibitors.